Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Equity Ratio (2019 - 2026)

C4 Therapeutics has reported Equity Ratio over the past 8 years, most recently at 0.71 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 16.63% year-over-year to 0.71; the TTM value through Mar 2026 reached 0.71, up 16.63%, while the annual FY2025 figure was 0.71, 15.66% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.71 at C4 Therapeutics, roughly flat from 0.71 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.71 in Q4 2025 and troughed at 0.58 in Q3 2025.
  • A 5-year average of 0.65 and a median of 0.65 in 2023 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 12.68% in 2022 and later increased 16.63% in 2026.
  • Year by year, Equity Ratio stood at 0.67 in 2022, then dropped by 2.61% to 0.65 in 2023, then fell by 5.5% to 0.62 in 2024, then grew by 15.66% to 0.71 in 2025, then decreased by 0.32% to 0.71 in 2026.
  • Business Quant data shows Equity Ratio for CCCC at 0.71 in Q1 2026, 0.71 in Q4 2025, and 0.58 in Q3 2025.